Last reviewed · How we verify

The TIMI Study Group — Portfolio Competitive Intelligence Brief

The TIMI Study Group pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Unfractionated heparin SC Unfractionated heparin SC marketed
Unfractionated Heparin IV Unfractionated Heparin IV marketed Anticoagulant Antithrombin III (enhancer); indirect inhibitor of thrombin and Factor Xa Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Assistance Publique - Hôpitaux de Paris · 1 shared drug class
  2. Beijing Anzhen Hospital · 1 shared drug class
  3. Beijing Chao Yang Hospital · 1 shared drug class
  4. Beijing Suncadia Pharmaceuticals Co., Ltd · 1 shared drug class
  5. Boston Scientific Corporation · 1 shared drug class
  6. CCRF Consulting Co., Ltd. · 1 shared drug class
  7. Deutsches Herzzentrum Muenchen · 1 shared drug class
  8. Anemia Working Group Romania · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for The TIMI Study Group:

Cite this brief

Drug Landscape (2026). The TIMI Study Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/the-timi-study-group. Accessed 2026-05-14.

Related